Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas
- 4 March 2005
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 328 (1) , 125-129
- https://doi.org/10.1016/j.bbrc.2004.12.164
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Transplantation of prodrug-converting neural progenitor cells for brain tumor therapyCancer Gene Therapy, 2003
- Purified herpes simplex virus thymidine kinase retroviral particles:Cancer Gene Therapy, 2002
- Efficacy of the bystander effect in the herpes simplex virus thymidine kinase-mediated gene therapy is influenced by the expression of connexin43 in the target cellsCancer Gene Therapy, 2001
- Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cellsGene Therapy, 2001
- A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma MultiformeHuman Gene Therapy, 2000
- Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological studyJournal of Neurosurgery, 2000
- Neural Precursor Cells for Delivery of Replication-Conditional HSV-1 Vectors to Intracerebral GliomasMolecular Therapy, 2000
- In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirusCancer Gene Therapy, 2000
- Bystander Effect-Mediated Therapy of Experimental Brain Tumor by Genetically Engineered Tumor CellsHuman Gene Therapy, 1998
- The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctionsGene Therapy, 1997